Q-omics provides the consensus-scored LRRC8C-DT profile across patient tissues and cancer cell-line models. LRRC8C-DT expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, LRRC8C-DT is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, LRRC8C-DT RNA expression shows 18,475 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight PAAD, THCA, and UVM as cancer lineages where LRRC8C-DT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRRC8C-DT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRRC8C-DT survival associations across molecular data types. LRRC8C-DT RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRRC8C-DT RNA expression–survival associations across cancer types. High LRRC8C-DT expression shows unfavorable associations in UCEC and LUSC, but favorable associations in PAAD, BRCA, CESC and LUAD. The PAAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify PAAD as the clearest survival context for LRRC8C-DT RNA expression.
This table summarizes LRRC8C-DT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for LRRC8C-DT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRRC8C-DT shows lower tumor expression in THCA, KICH, KIRP, UCEC and BRCA and higher tumor expression in HNSC. The THCA box plot shows higher LRRC8C-DT RNA expression in normal versus tumor tissue (log2 FC = −0.741, t-test p < 0.001).
This table shows molecular features associated with LRRC8C-DT in patient tissues and cancer cell lines. In patient samples, LRRC8C-DT shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
